

Giulia Magnani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11308164/publications.pdf>

Version: 2024-02-01

36
papers

2,513
citations

516561

16
h-index

395590

33
g-index

37
all docs

37
docs citations

37
times ranked

3533
citing authors

#	ARTICLE	IF	CITATIONS
1	Ischemic-hemorrhagic balance in diabetic and non-diabetic patients after acute coronary syndrome. REC: CardioClinics, 2022, 57, 203-211.	0.1	1
2	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association, 2021, 10, e017008.	1.6	17
3	Potential Relation between Plasma BDNF Levels and Human Coronary Plaque Morphology. Diagnostics, 2021, 11, 1010.	1.3	6
4	Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	1.6	7
5	Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. Minerva Cardiology and Angiology, 2021, 69, 408-416.	0.4	3
6	346 Baroreflex sensitivity and autonomic function in Takotsubo syndrome long after the acute phase. European Heart Journal Supplements, 2021, 23, .	0.0	1
7	345 Blood pressure and autonomic function in essential hypertension: comparative evaluation of 24-hour heart rate variability and blood pressure. European Heart Journal Supplements, 2021, 23, .	0.0	0
8	347 From arterial hypertension to left ventricular hypertrophy and heart failure: role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. European Heart Journal Supplements, 2021, 23, .	0.0	0
9	338 Autonomic function and hyper-adrenergic tone despite beta-blockers in chronic coronary syndrome with preserved ejection fraction: prevalence and related factors. European Heart Journal Supplements, 2021, 23, .	0.0	0
10	Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. European Journal of Preventive Cardiology, 2020, 27, 696-705.	0.8	28
11	Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries. American Journal of Cardiovascular Drugs, 2020, 20, 259-269.	1.0	12
12	P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 31-42.	1.4	37
13	Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries. American Heart Journal, 2020, 220, 108-115.	1.2	26
14	Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal, 2020, 41, 1625-1632.	1.0	27
15	Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. International Journal of Cardiology, 2020, 301, 200-206.	0.8	26
16	Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. Expert Review of Cardiovascular Therapy, 2020, 18, 881-889.	0.6	3
17	Incidencia anual de trombosis del stent confirmadas y factores clínicos predictores en pacientes con SCA tratados con ticagrelor o prasugrel. Revista Espanola De Cardiologia, 2019, 72, 298-304.	0.6	4
18	Annual Incidence of Confirmed Stent Thrombosis and Clinical Predictors in Patients With ACS Treated With Ticagrelor or Prasugrel. Revista Espanola De Cardiologia (English Ed), 2019, 72, 298-304.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 215-223.	0.4	4
20	Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 381-391.	1.0	16
21	Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 536-542.	0.4	15
22	Utilidad de la puntuaci3n PARIS para evaluar el equilibrio isqu3mico-hemorr3gico con ticagrelor y prasugrel tras un s3ndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 215-223.	0.6	6
23	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. <i>Journal of the American Heart Association</i> , 2018, 7, e009260.	1.6	8
24	Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry. <i>Thrombosis Research</i> , 2018, 167, 142-148.	0.8	19
25	Efficacy and Safety of Ticagrelor OverTime in Patients With Prior MI inPEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1368-1375.	1.2	74
26	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. <i>European Heart Journal</i> , 2016, 37, ehv482.	1.0	70
27	Efficacy and Safety of Novel Oral Anticoagulants in Patients With AtrialFibrillation and Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 870-880.	1.9	58
28	Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. <i>European Journal of Heart Failure</i> , 2016, 18, 1153-1161.	2.9	73
29	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease. <i>JAMA Cardiology</i> , 2016, 1, 795.	3.0	68
30	Impact of Sex on 2-Year Clinical Outcomesin Patients Treated With6-Month or 24-Month Dual-Antiplatelet Therapy Duration. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1780-1789.	1.1	23
31	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. <i>JAMA Cardiology</i> , 2016, 1, 425.	3.0	88
32	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. <i>European Heart Journal</i> , 2016, 37, 1133-1142.	1.0	138
33	Dual Antiplatelet Therapy After Drug-eluting Stent Implantation. <i>Interventional Cardiology Review</i> , 2016, 11, 51.	0.7	6
34	Editorial on PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 217-219.	1.4	1
35	Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States. <i>Journal of the American Heart Association</i> , 2015, 4, e001505.	1.6	62
36	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. <i>New England Journal of Medicine</i> , 2015, 372, 1791-1800.	13.9	1,585